Mersana Therapeutics MRSN 深 沪
等待开盘 11-21 09:30:00 美东时间
27.51
-0.100
-0.36%
华盛通- 最 高28.00
- 今 开27.89
- 成交量 12.10万股
- 最 低 27.26
- 昨 收 27.61
- 总市值 1.38亿
- 52周最高 70.73
- 市盈率 静 --
- 换手率 2.42%
- 52周最低 5.21
- 委 比 79.05%
- 总股本 499.88万
- 历史最高 727.25
- 量 比 0.15
- 振 幅 2.68%
- 历史最低 6.4725
- 每 手 1
- 风险率 14.12%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Mersana Therapeutics Q3 EPS $(1.51) Beats $(1.96) Estimate, Sales $11.009M Miss $14.203M Estimate
Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(1.51) per share which beat the analyst consensus estimate of $(1.96) by 23.12 percent. This is a 32.89 percent increase over losses of $(2.25) per share
11-14 20:02
Earnings Scheduled For November 14, 2025
Companies Reporting Before The Bell • Inhibrx Biosciences (NASDAQ:INBX) is expe...
11-14 19:11
美股牛股 | 美国火箭制造商Firefly涨17%，Q3业绩超预期且中标多项合同；希悦尔涨近17%
美国火箭制造商FLY涨17%，Q3业绩超预期且中标多项合同；希悦尔涨近17%，与私募公司就私有化进行谈判>>
11-14 18:48
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial Results
Mersana Therapeutics, Inc. has agreed to be acquired by Day One Biopharmaceuticals, Inc. The deal includes an upfront cash consideration of $25.00 per share and potential contingent value rights of up to $30.25 per share, with a total deal value of approximately $285 million. Closing is expected by the end of January 2026. Mersana's third-quarter 2025 financials showed a net loss of $7.5 million, with cash and cash equivalents at $56.4 million. ...
11-14 12:00
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
股价暴涨209.24%！Day One2.85亿美元收购Mersana Therapeutics，获得一款B7-H4 ADC
（来源：invest wallstreet） 11月13日，加利福尼亚州布里斯班，致力于为患有危及生命疾病的所有年龄段的人开发靶向疗法并将其商业化的生物...
11-14 07:41
BTIG Downgrades Mersana Therapeutics to Neutral
BTIG analyst Justin Zelin downgrades Mersana Therapeutics (NASDAQ:MRSN) from Buy to Neutral.
11-14 01:45
Mersana Therapeutics Earnings Preview
Mersana Therapeutics (NASDAQ:MRSN) is preparing to release its quarterly earnin...
11-14 00:02
Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout
Day One Biopharmaceuticals plans to acquire Mersana Therapeutics in a deal worth up to $285 million to expand its cancer drug portfolio.
11-13 23:15
Why Is Mersana Therapeutics Stock (MRSN) Up Today?
Mersana Therapeutics stock soared on Thursday alongside a huge deal with Day On...
11-13 20:42
